BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 7965756)

  • 1. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.
    Thummel KE; Shen DD; Podoll TD; Kunze KL; Trager WF; Bacchi CE; Marsh CL; McVicar JP; Barr DM; Perkins JD
    J Pharmacol Exp Ther; 1994 Oct; 271(1):557-66. PubMed ID: 7965756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.
    Thummel KE; Shen DD; Podoll TD; Kunze KL; Trager WF; Hartwell PS; Raisys VA; Marsh CL; McVicar JP; Barr DM
    J Pharmacol Exp Ther; 1994 Oct; 271(1):549-56. PubMed ID: 7965755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
    Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
    Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
    Gorski JC; Hall SD; Jones DR; VandenBranden M; Wrighton SA
    Biochem Pharmacol; 1994 Apr; 47(9):1643-53. PubMed ID: 8185679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
    Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
    Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
    Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
    Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
    Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
    Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation.
    Khan KK; He YQ; Domanski TL; Halpert JR
    Mol Pharmacol; 2002 Mar; 61(3):495-506. PubMed ID: 11854429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing midazolam hydroxylation activity in human liver microsomes.
    He P; Court MH; Greenblatt DJ; von Moltke LL
    Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe.
    Villeneuve JP; L'Ecuyer L; De Maeght S; Bannon P
    Clin Pharmacol Ther; 2000 Mar; 67(3):242-8. PubMed ID: 10741627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam.
    Yang J; Atkins WM; Isoherranen N; Paine MF; Thummel KE
    Clin Pharmacol Ther; 2012 Mar; 91(3):442-9. PubMed ID: 22048224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.
    Kharasch ED; Jubert C; Senn T; Bowdle TA; Thummel KE
    J Clin Pharmacol; 1999 Jul; 39(7):664-9. PubMed ID: 10392320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.
    Paine MF; Khalighi M; Fisher JM; Shen DD; Kunze KL; Marsh CL; Perkins JD; Thummel KE
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1552-62. PubMed ID: 9400033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
    Warrington JS; Poku JW; von Moltke LL; Shader RI; Harmatz JS; Greenblatt DJ
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1024-31. PubMed ID: 10688619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
    Lown KS; Kolars JC; Thummel KE; Barnett JL; Kunze KL; Wrighton SA; Watkins PB
    Drug Metab Dispos; 1994; 22(6):947-55. PubMed ID: 7895614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro.
    Oda Y; Mizutani K; Hase I; Nakamoto T; Hamaoka N; Asada A
    Br J Anaesth; 1999 Jun; 82(6):900-3. PubMed ID: 10562786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions.
    Blobaum AL; Bridges TM; Byers FW; Turlington ML; Mattmann ME; Morrison RD; Mackie C; Lavreysen H; Bartolomé JM; Macdonald GJ; Steckler T; Jones CK; Niswender CM; Conn PJ; Lindsley CW; Stauffer SR; Daniels JS
    Drug Metab Dispos; 2013 Dec; 41(12):2066-75. PubMed ID: 24003250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes.
    Quintieri L; Palatini P; Nassi A; Ruzza P; Floreani M
    Biochem Pharmacol; 2008 Mar; 75(6):1426-37. PubMed ID: 18191104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.